The present invention relates to a new pestivirus useful in the fields of veterinary virology and vaccines. Specifically, it relates to an isolated polynucleotide originating from pestivirus and a pestivirus, to vaccines and medical uses thereof, to chimeric virus comprising the polynucleotide and to expression vectors for heterologous expression of polypeptides.

An engineered Newcastle Disease Virus (NDV) vector is provided. In particular, the present disclosure provides methods of treating or preventing a disease such as cancer, or an infectious disease, or methods for eliciting an immune response, with the engineered NDV vector. The engineered NDV vector provided herein is useful as an immunogenic composition, an oncolytic agent, or a vaccine.

This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.

Provided are an F-genotype mumps virus attenuated strain, a construction method therefor and an application thereof. The attenuated strain is a mumps virus with the accession number of CCTCC NO: V201950. Further provided are a vaccine composition containing the F-genotype mumps virus attenuated strain as an active ingredient and a preparation method thereof.

Provided herein are methods for enhancing infection, growth, spread, or titer of an oncolytic RNA virus in a cancer or tumor cell; enhancing the oncolytic activity, cytokine-induced cell death activity, and/or cytotoxic activity of an oncolytic RNA virus in a cancer or tumor cell; upregulating cytokine response to, and/or enhancing the immunotherapeutic activity of an oncolytic RNA virus in a cancer or tumor cell; and/or treating a tumor or cancer in a subject in need thereof. Such methods employ a vanadium-containing compound, administered to the cancer or tumor cells before, after, or concurrently with infection of the cancer or tumor cells with the oncolytic RNA virus. Related compositions, uses, and kits therefor are also provided. Methods for producing RNA viruses, RNA virus-based cancer vaccines, and RNA virus-based cancer gene therapy vectors are also provided.

The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a arenavirus glycoprotein protein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order:—a further signal peptide of a Flavivirus NS1 protein,—an arenavirus Glycoprotein protein lacking the N terminal signal sequence and the GP2 transmembrane domain,—a TM1 and TM2 domain of a flaviviral E protein.

The present invention provides a modified influenza viruses comprising haemagglutinin and a headless haemagglutinin. The haemagglutinin is provided by a source exogenous to the virus and the headless haemagglutinin is encoded by the viral genome. The present disclosure also provides modified influenza viruses comprising a headless haemagglutinin. The present disclosure also provides vaccine compositions comprising the modified influenza viruses. The vaccine compositions of the present disclosure can elicit broad neutralizing antibodies and provide cross-protection across various influenza strains. Methods, compositions and cells for propagating the modified influenza viral strains related to vaccines is also provided.

The present invention provides an effective vaccine for Marek's disease, which may be prepared using a recombinant Marek's Disease Virus (MDV), strain CVI988, having been transformed with a foreign DNA construct that includes a long terminal repeat sequence of a reticuloendotheliosis virus. This safe viral agent elicits a highly protective immune response in a chicken against virulent MDV challenge without causing a significant degree of pathogenicity. Suitable formulations of the vaccine for use in chickens include an effective immunization dosage of this novel viral agent, along with a pharmaceutically acceptable carrier or diluent.

An H7 avian influenza vaccine strain which differentiates infected from vaccinated animals, a preparation method therefor, and an application. The highly pathogenic H7 avian influenza not only brings about huge economic losses to the livestock industry, but also seriously threatens public health safety. Conventional H7 avian influenza whole virus inactivated vaccines do have advantages such as being reliable in terms of effect, low in terms of cost and wide in terms of application range, but cannot serologically differentiate infected from vaccinated animals. The present invention uses NA of influenza B as a label to establish a method for constructing an H7 avian influenza vaccine strain which differentiates infection from vaccination, and may be used for the prevention, control and decontamination of the H7 avian influenza.

A buffer free, acid stable, low dose volume rotavirus vaccine is disclosed. The vaccine is available in dose volume of less than 1 ml per dose for oral administration and it is without any buffer. The vaccine also does not require pre or post administration of any antacid at the time of oral administration of the vaccine to the subject to neutralize the stomach acid. The vaccine exemplifies nominal drop in vaccine titer at pH 2-4 for a time span of 30 minutes. The vaccine is stable at −20° C. for at least 60 months.